Cambrex and Cytori Enter into Collaboration

Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, and Cytori Therapeutics have announced that they have entered into a strategic marketing agreement to provide adipose-derived stem cell products globally for use in basic and translational bioresearch.

Under the terms of the agreement, Cambrex Bio Science Walkersville, Inc. will manufacture and market products to the research community under the co-exclusive license from Cytori.

In return for the license, Cytori will receive royalties on all cells, media, and related future research products based upon the licensed technology.

Adipose tissue is known to contain a rich population of stem and progenitor cells that have been shown to possess significant regenerative properties in multiple clinical disciplines.

The licensing agreement brings together Cambrex Bio Science Walkersville, Inc. and Cytori.

"Adipose tissue is now a validated source of regenerative cells," said Shawn Cavanagh, Senior Vice President and General Manager, Cambrex Bioproducts business.

"The scientific potential of this population has only begun to be mined, yet already shows promise in clinical case studies."

"We look forward to offering the products to researchers that are conducting basic and preclinical research related to these cells."

"Our relationship with Cambrex ensures that scientists and physicians working on today's most challenging clinical problems including heart and neurological diseases have readily available access to our cell population," said Marc H. Hedrick, M.D., President of Cytori Therapeutics.

"Adipose is a dynamic tissue which, with further study, will help reveal previously hidden biological insights that could be applied toward the discovery of new therapies for a broad range of diseases."